Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Vor Biopharma Inc., a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients.
The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies.
It also offers Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system, currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system, made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, currently under preclinical studies for the treatment of AML.
Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases.
The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | -0.45 Decreased by -4.65% | -0.38 Decreased by -18.42% |
| Mar 20, 24 | -0.39 Increased by +25.00% | -0.50 Increased by +22.00% |
| Nov 7, 23 | -0.49 Increased by +22.22% | -0.47 Decreased by -4.26% |
| Aug 10, 23 | -0.45 Increased by +22.41% | -0.43 Decreased by -4.65% |
| May 11, 23 | -0.43 Increased by +29.51% | -0.38 Decreased by -13.16% |
| Mar 23, 23 | -0.52 Decreased by -8.33% | -0.60 Increased by +13.33% |
| Nov 10, 22 | -0.63 Decreased by -26.00% | -0.61 Decreased by -3.28% |
| Aug 11, 22 | -0.58 Decreased by -16.00% | -0.66 Increased by +12.12% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by N/A% | -33.19 M Decreased by -41.38% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -29.98 M Decreased by -39.27% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -26.44 M Decreased by -16.63% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -22.90 M Decreased by -25.46% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -23.48 M Decreased by -26.52% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -21.53 M Decreased by -17.18% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -22.67 M Decreased by -65.23% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -18.25 M Decreased by -16.53% | Decreased by N/A% Decreased by N/A% |